argenx to Present at Upcoming Investor Conferences

argenx to Present at Upcoming Investor Conferences


May 27, 2026Amsterdam, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in June:

  • William Blair 46th Annual Growth Stock Conference. Presentation on Wednesday, June 3, 2026 at 12:40 p.m. CT in Chicago, IL.
  • Goldman Sachs 47th Annual Global Healthcare Conference. Fireside chat on Tuesday, June 9, 2026 at 4:00 p.m. ET in Miami, FL.

A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit  www.argenx.com  and follow us on LinkedIn, Instagram, Facebook, and YouTube.

Contacts

Media:

Ben Petok
bpetok@argenx.com

Investors:

Alexandra Roy
aroy@argenx.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ARGX
The Conversation (0)
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

KELOWNA, BC / ACCESS Newswire / June 25, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14th with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral... Keep Reading...
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule

Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule

Potentially Valuable Novel Compositions Being InvestigatedLexaria Also Receives Additional New Granted Patent KELOWNA, BC / ACCESS Newswire / June 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following... Keep Reading...
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand

GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand

More People Than Ever Taking GLP-1 Drugs for Weight Loss Growing List of Diseases Now Indicated as Treatable With GLP-1 Drugs KELOWNA, BC / ACCESS Newswire / June 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms,... Keep Reading...
GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand

GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand

(TheNewswire) More people than ever taking GLP-1 drugs for weight loss Growing list of diseases now indicated as treatable with GLP-1 drugs Kelowna, British Columbia TheNewswire - June 17, 2026 Lexaria Bioscience Corp. (Nasdaq: LEXX) (the "Company" or "Lexaria"), a global innovator in drug... Keep Reading...
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.

(TheNewswire) Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECHâ„¢ Kelowna, British Columbia - June 9, 2026 TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery... Keep Reading...
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECHâ„¢ KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that dosing... Keep Reading...

Interactive Chart

Latest Press Releases

Related News